Cancer-stricken founder deploys AI in fightback

# Connor Christou # Keragon

Conno Christou refuses to leave his health to chance. He monitors his sleep with a Whoop band, cross-references the data with an Oura ring, and undergoes nearly 100 biomarker tests annually. For four consecutive years, he followed the bloodwork protocols of longevity experts like Peter Attia and Rhonda Patrick, optimizing his supplements, circadian rhythm, and protein intake. At 35, while launching his second company, he was as attuned to the latest health research as anyone in his circle. His 2025 checkup showed green across the board. “It was the best I’d had in years,” he recalls. Then, after a workout, his arm swelled. He initially dismissed it. A week later, a doctor discovered two blood clots in his veins and scheduled surgery. But pre-op exams changed everything. A doctor entered the room and canceled the procedure. “We see an 11-by-11-by-8 centimeter mass behind your sternum,” the doctor explained. A biopsy confirmed a diagnosis Christou had never considered: aggressive, fast-growing non-Hodgkin’s lymphoma. This rare condition, affecting roughly one in 420,000 people, stems from a random genetic mutation unrelated to lifestyle, diet, or stress. The tumor had existed for only three months. Within three more weeks, it would have reached stage four. “Lucky in my unluckiness,” Christou told this editor from his Athens home, where he splits his time. “It was only found because I went in for something else entirely.” This experience became a lesson in the medical system’s limits and what a proactive patient can achieve with modern tools. His first oncologist, a renowned specialist, recommended the milder of two chemotherapy regimens. Christou scheduled his first infusion three days later. The night before, he sought a second opinion. That second doctor recommended the more aggressive regimen: continuous in-hospital infusions, cycling every three weeks for six months, based on Christou’s specific pathology. The lighter treatment offered a 60% success rate for his case; the aggressive one raised it to 85%. Two world-class doctors offered diametrically opposite advice. “As founders, we hold the wheel,” Christou says, noting why patients should not simply accept the first recommendation. “You hear many things. You don’t have to follow the first advice.” He did not rely on just one second opinion. Over two days, he gathered 12 perspectives, leveraging his professional network to contact hematologists and oncologists in the US and abroad. Eleven out of twelve recommended the aggressive path. He chose it, viewing the decision as logical rather than brave. When stakes are existential, you collect data. Over six months, Christou approached chemotherapy like building a company: a marathon of sprints, each with finite cycles and weekly data points. Having completed 25 months of mandatory military service in Cyprus at age 18, he drew on that discipline. He resolved to be a good soldier, trust the process, and complete six cycles. He wore his Whoop band throughout treatment, finding it highly accurate at predicting immune system lows, often flagging them before symptoms appeared. He maintained a symptom journal via voice transcription, logging every shift, side effect, and medication. He focused on three variables: sleep, nutrition, and psychology. (“It moves the needle more than anything,” Christou says. “I never asked ‘why me’ — not once. That question has no useful answer.”) He fed all data—blood results, scans, wearable output, journal entries—into Claude. He is not alone in using chatbots for medical guidance. A March public opinion poll revealed that one-third of American adults now use them for health information. Online stories suggest AI is delivering what the system sometimes fails to provide. Experts urge caution. Danielle Bitterman, clinical lead for data science and AI at Mass General Brigham, recently told the New York Times that general-purpose chatbots are frequently wrong and “have not been thoroughly evaluated” for personalized diagnoses. Christou agrees. “It didn’t replace the doctors,” he says, but it “helped me ask the right questions.” For a condition as rare as his—seen by an oncologist once a year—access to a model trained on the full body of medical literature was, he notes, far more powerful than a standard Google search. This distinction proved critical at treatment’s end. His final PET scan, used to detect active disease, returned ambiguous results. His oncologist began discussing second-line therapy, potentially radiotherapy near his heart and lungs, an alarming development. Christou did his homework. He learned that for this specific lymphoma, the false-positive rate on end-of-treatment PET scans is around 60%—a statistic that still astonishes him. “It’s 2026,” he says. “Sixty percent.” He fed all three PET scans and his MRI into Claude, which flagged a known but easily overlooked phenomenon: in patients under 40 recovering from this lymphoma, the thymus gland can reactivate after chemotherapy, appearing on imaging as active disease. Given his age and scan characteristics, the model estimated a 90% probability of this explanation. He sought three more opinions. The fourth doctor confirmed it: thymus rebound. There was no active disease, and no radiotherapy was needed. He was clear. Christou is still processing what the last year has meant for his health, work, and perspective on time. He built Keragon, his current company, before this crisis; it is an AI-powered platform helping medical practices automate administrative operations. However, experiencing the system as a patient gave him new insight. He watched healthcare professionals buried in tasks unrelated to care. He received the same chemotherapy protocol as an 80-year-old woman, with side effects managed by a cascade of additional drugs, each causing its own problems. He is certain we will look back on this era of treatment with cringe. He now takes Sundays off, mostly. He strives to be present—at lunches with friends, at home with his dog, in conversations once dismissed as distractions. A VC friend told him years ago to “Be happy now,” a phrase he replayed during treatment. He acknowledges it is among the hardest things to do, yet he now appreciates its importance. He offers to speak with anyone undergoing similar experiences to share notes and compare journeys. He means it. “It’s not happening in 10 years,” he says of what AI can already do for patients willing to use it. “It’s happening today.”

Related article

Comments (0)